Brendan P. O'Grady - 08 Oct 2026 Form 4 Insider Report for Nasus Pharma Ltd (NSRX)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
13 Nov 2026, 19:35:12 UTC
Prior SEC filing
31 Jul 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Brendan O'Grady
Filing notes and source

Key filing fact

Brendan P. O'Grady filed Form 4 for Nasus Pharma Ltd (NSRX) on 13 Nov 2026.

Key facts

  • This page summarizes Brendan P. O'Grady's Form 4 filing for Nasus Pharma Ltd (NSRX).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 13 Nov 2026, 19:35.

Change

  • Previous filing in this sequence was filed on 31 Jul 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001726533 Primary reporting owner

O'Grady Brendan P.

Relationship
Chief Executive Officer, Director
Address
P.O. BOX 284, TEL-AVIV-YAFO, ISRAEL
Signature
/s/ Brendan O'Grady
Signature date
13 Nov 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NSRX transaction Derivative

Share options (right to buy)

Award

Transaction value
Shares
+210,000
Change %
Price
Shares after
210,000
Date
08 Oct 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
210,000
Exercise price
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Options to purchase 210,000 ordinary shares of the Issuer, no par value ("Ordinary Shares"), were granted on July 27, 2026, with one-third of such options, representing 70,000 options, vesting on July 27, 2027, and the remaining two-thirds vesting in eight equal quarterly installments of 17,500 options, beginning on October 27, 2027. The foregoing options are part of the reporting person's compensation package as the Chief Executive Officer of the Issuer, which was approved by the Issuer's shareholders on October 8, 2026.

Footnote F2

Of the 210,000 options reported herein, the first one-third, representing 70,000 options, will be exercisable at $3.50 per Ordinary Share, the second one-third, representing 70,000 options, will be exercisable at $4.25 per Ordinary Share, and the final one-third, representing 70,000 options, will be exercisable at $5.00 per Ordinary Share; provided that the exercise price of an option may not be less than the Fair Market Value of an Ordinary Share, as defined pursuant to the Issuer's 2019 Incentive Option Plan, including, without limitation, the Sub-Plan for U.S. Persons, on the grant date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .